Pacific Biosciences of California PACB Change in fair value of contingent consideration
Change in fair value of contingent consideration at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's change in fair value of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's change in fair value of contingent consideration?
- Pacific Biosciences of California (PACB) reported change in fair value of contingent consideration of $0 in Q1 2026.
- How has Pacific Biosciences of California's change in fair value of contingent consideration changed year-over-year?
- Pacific Biosciences of California's change in fair value of contingent consideration increased by 100.0% year-over-year, from -$18.7M to $0.
- What is the long-term trend for Pacific Biosciences of California's change in fair value of contingent consideration?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's change in fair value of contingent consideration has grown at a 101.1% compound annual growth rate (CAGR), from $1.14M to -$18.7M.
- What does change in fair value of contingent consideration mean?
- Represents the non-cash adjustment to the fair value of earn-outs or other contingent payments owed to sellers in a business acquisition. Fluctuations in this value reflect changes in the probability or expected amount of future payouts based on performance targets.